1997 Fiscal Year Final Research Report Summary
Development of a simple screening system for the discovery of a new drug for diabetes
| Project/Area Number |
08558074
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Functional biochemistry
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
EBINA Yousuke The University of Tokushima, Institute for Enzyme Research, Professor, 分子酵素学研究センター, 教授 (00112227)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ASAHI Yoshihiko Otsuka Pharmaceutical Co., Ltd.Tokushima Institute, 徳島研究所, 研究員
KISHI Kazuhiro The University of Tokushima, Institute for Enzyme Research, Research Associate, 分子酵素学研究センター, 助手 (70284320)
HAYASHI Hideki The University of Tokushima, Institute for Enzyme Research, Associate Professor, 分子酵素学研究センター, 助教授 (10218589)
|
|---|
| Project Period (FY) |
1996 – 1997
|
| Keywords | drug for diabetes / glucose transporter |
|---|
| Research Abstract |
There are more than 5 million patients of diabetes and a new oral drug must be developed. However, there is not a simple and quantitative method to find the oral diabetic drug. Whole animal was used to find the new drug to estimate the decrease of blood glucose level, but this method is not adeguate toscreen a large number of compound. Translocation of the type 4 glucose transporter (GLUT4) to the cell surface from an intracellular pool is the major mechanism of insulin-stimulated glucose uptake in insulin-target cells. We developed a highly sensitive and quantitative method of detect GLUT4 immunologically on the surface of intact cells, using c-myc epitope-tagged GLUT4 (GLUT4myc). We established stable clones to express GLUT4myc in CHO,L6 myoblasts and 3T3L1 adipocytes. We have developed a simple and new method to screen the compounds for triggering the GLUT4myc translocation in 96 wells using luminessence method. This method is useful for the first screening for developing a new oral drug for diabetes.
|
